Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fontolizumab Protein Design Labs.

Francis J Dumont1

  • 1francisj_dumont@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary
This summary is machine-generated.

Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for autoimmune diseases. The company sought to outlicense its development and commercialization rights outside the US and Canada by February 2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel pharmacological modulators of autophagy and therapeutic prospects.

Expert opinion on therapeutic patents·2012
Same author

Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.

Current cancer drug targets·2012
Same author

Cytokines: the magic is still there.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fingolimod. Mitsubishi Pharma/Novartis.

IDrugs : the investigational drugs journal·2005
Same author

Technology evaluation: abatacept, Bristol-Myers Squibb.

Current opinion in molecular therapeutics·2004
Same author

ISAtx-247 (Isotechnika/Roche).

Current opinion in investigational drugs (London, England : 2000)·2004
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Autoimmune diseases pose significant challenges in treatment.
  • Interferon gamma plays a role in autoimmune conditions.
  • Monoclonal antibodies are a therapeutic class for immune modulation.

Purpose of the Study:

  • To investigate the potential of fontolizumab for treating autoimmune diseases.
  • To assess the commercial development strategy for fontolizumab.

Main Methods:

  • Development of fontolizumab, a humanized monoclonal antibody targeting interferon gamma.
  • Strategic business development activities to secure external partnerships.

Main Results:

  • Fontolizumab demonstrated potential as a therapeutic agent.

Related Experiment Videos

  • Active pursuit of outlicensing opportunities was underway.

    • Conclusions:

    • Fontolizumab represents a promising therapeutic candidate for autoimmune disorders.
    • External partnerships were sought to advance global development and commercialization.